DRUG ABUSE-RELATED STUDIES


Supporting your investigative, efficacy, and GLP regulatory requirements

GLP Regulatory Studies

Regulatory agencies require that any drug (parent or major metabolite) that penetrates the brain and has CNS activity, regardless of its therapeutic indication, be assessed for that drug's abuse/dependence potential. The following rodent nonclinical, fully GLP compliant studies are conducted at Covance:

GLP Drug Abuse/Dependence Liability Studies

- ► Self-administration
- ▶ Drug discrimination
- ► Physical dependency
- Bioanalysis and formulation analysis
- Consultancy services are available



Investigative/Efficacy Studies

In addition to our GLP regulatory portfolio of studies, we support your early investigative work by evaluating compounds for potential abuse risk; testing the efficacy of drugs to prevent or treat drug-use disorders; and assessing the analgesic activity of drugs for pain relief.

Investigative/Efficacy Studies	Pain Models (Other tests are available upon request)
► Self-administration cue reinstatement	▶ Tail flick
▶ Drug-induced behavioral sensitization	▶ Abdominal spasm
► Cannabinoid tetrad	▶ Randall-Selitto

A Nimble, Agile and Experienced Partner

Understanding the different study types, time-lines and logistics involved in the assessment of abuse potential for novel drugs can be challenging. Our experienced team will partner with you to provide additional expertise, time and capacity to support your program.

Let's Partner, Together.

Learn more at www.covance.com/drug-abuse

Covance Inc., headquartered in Princeton, NJ, USA, is the drug development business of Laboratory Corporation of America Holdings (LabCorp). COVANCE is a registered trademark and the marketing name for Covance Inc. and its subsidiaries around the world.



